Evidence map›Paper›PMID 20805403›Full record

ReviewMicrobiology and molecular biology reviews : MMBR2010

Microbe hunting.

W Ian Lipkin

Abstract readReview
In one paragraph

Review in Microbiology and molecular biology reviews : MMBR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Interpreting Viral Associations in Neurodegenerative Diseases.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Frontiers in neurology · 2019
    Article
  9. Article
  10. Review
  11. Virological and Immunological Outcomes of Coinfections.Clinical microbiology reviews · 2018
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Complementary approaches to diagnosing marine diseases: a union of the modern and the classic.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2016
    Review
  17. Review
  18. Article
  19. Article
  20. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases.Translational research : the journal of laboratory and clinical medicine · 2015
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

W Ian LipkinCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA. wil2001@columbia.edu

Funding

Viral Pathogenesis and TherapeuticsU54AI057158 · NIAID · WADSWORTH CENTER · PI LIPKIN, W. IAN · 2003 to 2014
$100.8M
Development of Complement Modulating Therapeutics for AMDR24EY017404 · NEI · UNIVERSITY OF UTAH · PI HAGEMAN, GREGORY S · 2006 to 2010
$14.8M
A Staged Strategy for Virus Identification and DiscoveryR01AI051292 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LIPKIN, W. IAN · 2002 to 2005
$2.0M
NEI NIH HHS R24 EY017404NEI NIH HHS R24-EY017404-03NIAID NIH HHS AI051292NIAID NIH HHS AI57158NIAID NIH HHS R01 AI051292NIAID NIH HHS U54 AI057158
6 · The paper itself

Abstract

Platforms for pathogen discovery have improved since the days of Koch and Pasteur; nonetheless, the challenges of proving causation are at least as daunting as they were in the late 1800 s. Although we will almost certainly continue to accumulate low-hanging fruit, where simple relationships will be found between the presence of a cultivatable agent and a disease, these successes will be increasingly infrequent. The future of the field rests instead in our ability to follow footprints of infectious agents that cannot be characterized using classical microbiological techniques and to develop the laboratory and computational infrastructure required to dissect complex host-microbe interactions. I have tried to refine the criteria used by Koch and successors to prove linkage to disease. These refinements are working constructs that will continue to evolve in light of new technologies, new models, and new insights. What will endure is the excitement of the chase. Happy hunting!

Indexed as

BacteriaBacterial InfectionsBacterial ProteinsCommunicable DiseasesHumansMetabolomicsProteomicsBacterial Proteins

Identifiers

PMID20805403
PMCPMC2937520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.